Illumina Launches BaseSpace® Apps

Illumina Launches BaseSpace® Apps

Beta Phase Ends, Platform Enables E-Commerce for Developers with Introduction of iCredits™

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (Nasdaq: ILMN  ) today announced the full commercial availability of BaseSpace, the Company’s genomics cloud computing and storage platform. BaseSpace Apps is now out of beta status, and includes a full-fledged e-commerce system that allows customers to quickly and easily purchase Illumina and third-party bioinformatics applications (apps). BaseSpace e-commerce transactions are based on BaseSpace iCredits, a medium of exchange that can be purchased and spent within BaseSpace.

BaseSpace has rapidly become a valuable platform for bioinformatics app developers. During the beta period, users launched individual BaseSpace apps more than 4,000 times. Now, with BaseSpace iCredits, developers can easily add e-commerce functionality to their apps, leveraging Illumina’s complete payment solution.

“The commercial availability of BaseSpace Apps is an important milestone for both Illumina customers and BaseSpace app developers. For customers, BaseSpace has transitioned into a fully-supported bioinformatics platform; for BaseSpace app developers, BaseSpace now has a comprehensive e-commerce capability that enables them to monetize their efforts,” said Alex Dickinson, Illumina’s Senior Vice President, Cloud Genomics. “With rapid adoption of BaseSpace by users of Illumina’s high-throughput HiSeq® next-generation sequencing systems, and the continued use of the platform by users of Illumina’s MiSeq® desktop sequencing systems, the scale of growth potential for BaseSpace Apps is increasing exponentially.”

“BaseSpace continues to attract a large number of app developers who can rapidly make their bioinformatics tools available to thousands of Illumina customers,” added Jordan Stockton, Illumina’s Director of Product Marketing, Computational Biology. “BaseSpace is designed to support apps that enable genomics research in diverse markets including cancer, microbiology, and genetic disease.”

Through the BaseSpace ecosystem, a diverse collection of new apps are now available for Illumina’s MiSeq and HiSeq systems. For example, Elsevier Publishing, the world’s leading publisher of scientific and health information, has released a BaseSpace app that enables users to submit data directly into the peer-review publication process.

“We’re excited to be working with Illumina to accelerate the scientific publication process,” said Bart Wacek, Executive Publisher, Elsevier Life Sciences. “Through BaseSpace, scientists can directly submit their data and manuscript to our Genomics Data journal, allowing the data review to be an integral part of the peer-review process.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for BaseSpace Apps and related data analysis applications and programs. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.



Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2434960, ~/Articles/ArticleHandler.aspx, 12/19/2014 8:54:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...